Gilead Sciences has secured a major regulatory victory as the European Commission approved the combination of Trodelvy and Keytruda for treating adult patients with unresectable, locally advanced or metastatic triple negative breast cancer. The authorization specifically covers patients who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score, opening a new treatment avenue for one of the most aggressive forms of breast cancer.
Triple negative breast cancer accounts for approximately 15 percent of all breast cancers and is notoriously difficult to treat due to the absence of hormone receptors and HER2 protein that other therapies target. The newly approved combination pairs Gilead’s antibody drug conjugate Trodelvy with Keytruda, a checkpoint inhibitor marketed by Merck Sharp & Dohme, creating a dual mechanism approach to fighting the disease.
The European Commission decision follows closely on the heels of another recent approval for Trodelvy as monotherapy in similar patient populations who are not candidates for PD-1 or PD-L1 inhibitor therapy. This dual authorization strategy provides oncologists with flexibility in tailoring treatment based on individual patient characteristics and biomarker profiles.
Gilead shares rose 0.38 percent to $146.68 in pre-market trading following the announcement, reflecting investor confidence in the expanding commercial opportunity for Trodelvy across European markets. The approvals position Gilead to capture significant market share in the metastatic triple negative breast cancer treatment landscape.
Leave a comment